Diabetes mellitus (DM) is an important endocrine disorder of dogs. The objectives of this study were to estimate prevalence and incidence of DM in dogs, and to explore risk factors for DM and the survival of DM cases in primary-care clinics in the UK.
A case-control study nested in the cohort of dogs (n = 480,469) aged ≥3 years presenting at 430 VetCompass clinics was used to identify risk factors for DM, using multivariable logistic regression. Overall 409 new and 863 pre-existing DM cases (total 1272) were identified in 2016, giving an apparent annual prevalence of 0.26% (95% confidence interval (CI): 0.25–0.28%), and an annual incidence risk of 0.09% (95%CI: 0.08–0.09%) in dogs aged ≥3 years. Factors associated with increased odds for DM diagnosis were all age categories > 8 years, female entire dogs (odds ratio (OR): 3.03, 95% CI 1.69–5.44, p < 0.001) and male neutered dogs (OR: 1.99, 95% CI 1.18–3.34, p = 0.010) compared to male entire dogs, Border Terriers (OR: 3.37, 95% CI 1.04–10.98, p = 0.043) and West Highland White Terriers (WHWT) (OR: 2.88, 95% CI 1.49–5.56, p = 0.002) compared to crossbreeds. Dogs that had received previous glucocorticoid treatment (OR: 2.19, 95% CI 1.02–4.70, p = 0.044) and those with concurrent conditions (documented obese, pancreatitis, hyperadrenocorticism) also had increased odds for DM diagnosis.
Cox regression modelling was used to evaluate factors associated with survival in the 409 incident DM cases in 2016. Increased hazard of death following diagnosis of DM was shown in dogs that were ≥ 10 years age, Cocker Spaniels (HR: 2.06, 95% CI 1.06–4.01, p = 0.034) compared to crossbreeds, had a blood glucose (BG) level at diagnosis > 40 mmol/L (HR: 2.73, 95% CI 1.35–5.55, p = 0.005) compared to < 20 mmol/L at diagnosis, or had received previous glucocorticoid treatment (HR: 1.86, 95% CI 1.21–2.86, p = 0.005). Dogs at reduced hazard of death included neutered dogs (HR: 0.58, 95% CI 0.42–0.79, p = 0.001), Border Collies (HR: 0.39, 95% CI 0.17–0.87, p = 0.022) and those starting insulin treatment (HR: 0.08 95% CI 0.05–0.12, p < 0.001).
Certain breeds and concurrent health conditions are associated with an increased risk of DM. In addition to certain signalment factors, a high BG level at diagnosis and prior glucocorticoid treatment were adversely associated with survival of dogs with DM.
Plain English summary
Diabetes mellitus (DM) is a serious disease that can compromise the welfare of dogs. This study looked at factors associated with the risk of dogs developing DM, and also factors associated with how long they might survive with the disease.
The study compared 409 dogs from UK primary-care practice diagnosed with DM in 2016, with 818 dogs without DM. Dogs that were more likely to be diagnosed with DM included those that were older than 8 years, female dogs that were not neutered, male dogs that were neutered, Border Terriers, West Highland White Terriers (WHWTs), those who had previous been on glucocorticoid (steroid) medication, and those with other health conditions such as obesity, pancreatitis or hyperadrenocorticism. Conversely, Staffordshire Bull Terriers (SBT), Shih-tzus and German Shepherd Dogs (GSDs) were less likely to develop DM.
For the survival of dogs with DM, factors associated with decreased survival included dogs > 10 years old at diagnosis, Cocker Spaniels, those with very high blood glucose readings at diagnosis with DM, or those who had previously been on glucocorticoid (steroid) medication. Factors associated with increased survival included dogs that were neutered, Border Collies and dogs starting insulin treatment.
Diabetes mellitus (DM) is a relatively common endocrinopathy of dogs, with an estimated prevalence of approximately 0.32–0.36% [1,2,3]. Clinical DM in dogs is characterised by the loss of pancreatic islet cells resulting in insulin deficiency and persistent hyperglycaemia, resulting in clinical signs including polyuria, polydipsia, polyphagia and weight loss [4, 5]. Both genetic and environmental factors are implicated in the development of this disease . Although the exact pathogenesis leading to islet cell loss is often unclear , and is likely to be heterogeneous, there are thought to be similarities between some cases of DM in dogs and type 1 diabetes mellitus (T1DM) in humans [7,8,9]. The incidence of T1DM has been increasing worldwide , and the speed of this rise suggests it is not solely related to genetic factors. The prevalence of DM in dogs is reported to be increasing, up by 79.7% since 2006 in the US [11, 12], and highlights a need for a greater understanding of the current frequency and risk factors in the development of the disease.
Factors reported to be associated with the development of DM in dogs include genetics, age, sex, neutering status, obesity, drug therapy, infection and concurrent disease [9, 13]. Juvenile-onset diabetes before 1 year of age in dogs is uncommon , and is more likely to have a familial element . DM is more commonly diagnosed in middle-aged to older dogs [8, 11, 15], typically in dogs over 5 years of age. Although reported breed predispositions vary between countries, certain breeds appear predisposed including Samoyeds [7, 11, 16, 17], miniature schnauzers [7, 11, 17], Cairn terriers [11, 13, 15, 17,18,19] and Yorkshire terriers [2, 14]. Conversely German Shepherd Dogs (GSD), Golden retrievers [2, 17] and Boxers appear at a reduced risk [3, 13, 15, 16]. There has been inconclusive evidence for sex and neuter status as risk factors, likely related to the varying neutering practices internationally. Where it is not common practice to neuter female dogs, dioestrus-associated diabetes is more common. This is related to the antagonising effects on insulin from progesterone, as well as growth hormone released from the canine mammary glands under the influence of progesterone . Some studies show females at increased risk compared to males [11, 15, 16, 21], and neutered males at increased risk compared to entire males [2, 3, 11]. However it is unclear whether sex alone is associated with DM [1,2,3, 14, 19, 22], and some studies also failed to identify association with neutering, though may be limited by their small sample sizes [19, 22].
Obesity has been associated with both human type 2 diabetes mellitus (T2DM), and feline diabetes , but there is limited evidence about the role of obesity in the development of DM in dogs [6, 23]. Obesity-induced insulin resistance has been documented in dogs, but it appears that dogs are resistant to developing type 2 diabetes . A number of studies have identified being overweight/obese as risk factors for DM in dogs [2, 25, 26]. Conversely one small study reported an association with underweight dogs, but because body condition score (BCS) was assessed by the veterinarian at the time of diagnosis, this may reflect consequential weight loss associated with the DM rather than as a true predictive risk factor .
Diabetes mellitus in dogs has been associated with co-morbidities such as hyperadrenocorticism, urinary tract infections (UTI), dermatitis, otitis, pancreatitis and hypothyroidism [2, 3, 14, 17, 27]. Hyperadrenocorticism is the most commonly associated endocrinopathy with DM [17, 28, 29], and has been identified as a risk factor [2, 16], which is most likely related to the cortisol antagonism of insulin. Immune-mediated insulitis and exocrine pancreatic disease are also thought to play a role in the pathogenesis of DM [1, 30, 31] and, although the exact relationship between the two diseases is not entirely clear , pancreatitis is commonly found concurrently with DM [2, 3, 17, 33, 34]. One study found pancreatitis was associated with increased risk of DM, and with decreased survival .
The few studies that have reported on the survival of dogs with DM have provided little agreement on the median survival time (MST) [2, 16, 34, 35]. A study of insured dogs in Sweden reported a MST of 57 days from the date of the first insurance claim across all cases, increasing to 2 years for dogs surviving at least 1 day . Comparatively, a study of English primary-care practices and a study from a referral hospital in Italy reported MST as 17.3 months  and 32 months  respectively. A study surveying veterinarians reported that 1 in 10 dogs were euthanised at diagnosis and another 1 in 10 euthanised within 1 year, most commonly due to concurrent conditions, cost considerations and age . Little is known about the risk factors for survival in dogs with DM, particularly in a primary care setting. Pancreatitis and old age have been associated with a higher hazard of death, whereas neutered and insured dogs had lower hazard . Another study found no association with age, nor with a previous diagnosis of pancreatitis, but breed affected survival time . However these studies have been limited by relatively short follow up time [2, 16], or being restricted to referral populations , and none have investigated the prognostic impact of the initial management of the condition on subsequent survival.
The aim of this study was to estimate prevalence and incidence of DM in a large population of dogs under primary veterinary care in the UK, and to investigate risk factors for DM and the survival of DM cases. Secondary aims were to describe the current diagnostic processes and early DM management as well as exploring associations between these and survival. A greater understanding of the risk factors involved in the development of DM, and prognostic indicators for survival, can help inform genetic studies and allow population stratification for clinical trials as well as aiding primary care clinicians in identifying individuals at risk and in providing owners with prognostic information.
The study population consisted of 480,469 dogs aged ≥3 years on 01/01/2016 under veterinary care at 430 primary-care UK-wide VetCompass practices during the study period. The median age was 6.7 years (range: 3.0–20.2 years), 48.2% (231,524) were female, and 56.4% (271,068) were neutered. Within this population, 409 new (incident) and 863 pre-existing DM cases (total 1272) were identified in 2016, giving an apparent annual prevalence of 0.26% (95% confidence interval (CI): 0.25–0.28%), and an annual incidence risk of 0.09% (95%CI: 0.08–0.09%) in dogs aged ≥3 years.
Of the 409 incident DM cases in 2016, 48.9% (200) were female, and 70.7% (289) were neutered, 77.5% (317) were classified purebred and 32.5% (133) were insured. The median age at diagnosis was 10.0 years (range: 3.2–18.0 years). For those dogs where diagnostic test information was recorded electronically (392), nearly all diagnoses included blood testing (96.9%, 380/392), and the majority had a combination of blood testing and urinalysis (76.0%, 298) (Table 1). Dogs that were ketotic at diagnosis (32.8%, 134), and dogs with cataracts present within 3 months after diagnosis (32.8%, 134) both accounted for approximately a third of cases each. Recorded blood glucose (BG) levels at diagnosis ranged between 12.2–51.7 mmol/L, median 28.1 mmol/L. Most dogs (90.1%, 362) were started on insulin treatment, most commonly twice daily injections (68.3%, 224). There was no information on insulin treatment for 1.7%  of dogs. Of those dogs not receiving insulin treatment (9.8%, 40), only 17.5% (7/40) survived > 7 days, and of these dogs only 1 received another drug (acarbose). There were 16.1% (66) of dogs hospitalised at diagnosis, and only 5.9%  were referred for advanced management.
Where monitoring of DM in the first 3 months was recorded (88.3%, 361), 90% primarily involved blood testing (324/361), which consisted of haematology, biochemistry, BG measurements, and/or fructosamine analyses. The most common monitoring approaches were home or practice BG curves (70.6%, 255) and/or spot BG (68.4%, 247). Only 15 (4.2%) of the dogs were managed with spot BG alone and no other tests. Almost half of dogs (44.3%, 160) had urinalysis as part of their monitoring, and a similar percentage (41.3%, 149) had a diet change recommended. “Other” management techniques were used in 35.5% (128) of cases, and in most cases, this was fluid therapy.
The results of univariable logistic analysis are described in Table 2. There were strong associations with the following variables: age at diagnosis, neutering status, sex combined with neutering status, bodyweight, breed, obesity, prior treatment with glucocorticoids, a concurrent diagnosis of hyperadrenocorticism or pancreatitis, insurance status and veterinary group. Purebred status was associated at p < 0.2, and sex alone was not associated with diagnosis of DM.
The final multivariable model (Table 3) included eight variables, and appeared to explain the data well (Hosmer-Lemeshow p = 0.999). Clustering at clinic level was not significant when clinic ID was added as a random effect (p = 0.497). Veterinary group confounded associations with age at diagnosis, sex combined with neutering, concurrent conditions, and breed, and was therefore included as a fixed effect. After adjusting for the other variables in the model, an increased odds for DM diagnosis was seen with age > 8 years old (OR peaking at 10 to < 13 years old), and female entire dogs (OR: 3.03, 95% CI 1.69–5.44, p < 0.001) and male neutered dogs (OR: 1.99, 95% CI 1.18–3.34, p = 0.010) compared to male entire dogs. With male entire dogs as a baseline category in the sex-neuter variable there was no significant difference between the ORs for female entire dogs (OR: 3.03, 95% CI 1.69–5.44) and female neutered dogs (OR: 1.36, 95% CI 0.80–2.31). Border Terriers (OR: 3.37, 95% CI 1.04–10.98, p = 0.043) and West Highland White Terriers (WHWT) (OR: 2.88, 95% CI 1.49–5.56, p = 0.002) compared to crossbreeds were also associated with increased odds for DM, as were those documented obese (OR: 2.71, 95% CI 1.63–4.52, p < 0.001), or had a concurrent diagnosis of pancreatitis (OR: 1085.19, 95% CI 36.36–32,390.61, p < 0.001) or hyperadrenocorticism (OR: 11.28, 95% CI 2.41–52.73, p = 0.002). Compared to crossbreds, breeds with reduced odds of DM included Staffordshire Bull Terriers (SBT) (OR: 0.42, 95% CI 0.18–0.98, p = 0.046), Shih-tzu (OR: 0.20, 95% CI 0.04–0.96, p = 0.045) and German Shepherd Dogs (GSD) (OR: 0.08, 95% CI 0.01–0.74, p = 0.025).
There were 252 (61.6%) deaths from all-cause mortality prior to February 2020; of these, 147 (58.3%) were directly attributable to DM and 233 (92.5%) were euthanised. More than one reason was often given for a euthanasia decision, and the most frequent reason cited was worsening of DM clinical signs, cited in 58.4% (136/233) of euthanasia decisions (Table 4). This was closely followed by contributory conditions which were cited in 57.1% (133/233) of euthanasia decisions. Contributory conditions most frequently included ocular disorders, contributing to 14.2% (33/233) of euthanasia decisions, followed by pancreatitis, neoplasia and non-specific poor quality of life, each contributing to 7.3% (17/233) of all euthanasia decisions.
Median survival time from diagnosis for all dogs was 15.6 months (95% CI: 10.4–20.0), and for those surviving at least 7 days post DM diagnosis, MST was 20.2 months (95% CI: 16.6–24.7).
The results from univariable cox regression are described in Table 5. There were strong associations (p ≤ 0.001) with survival for the following variables: age, neutering status, insulin treatment, and monitoring methods that included BG curves at the practice, spot BG, fructosamine measurements or a recommended diet change. Other variables associated at p < 0.2 included: sex, combined sex and neuter status, insurance, breed, being ketotic at diagnosis, prior glucocorticoid treatment, obesity, BG level at diagnosis, and monitoring methods including bloods (unspecified) and urinalysis.
The final multivariable model showed survival to be associated (p < 0.05) with age, neutering status, insulin treatment, prior glucocorticoid treatment, and BG level at diagnosis (Table 6). Dogs within the following categories showed increased hazard of death following diagnosis of DM: both age categories ≥10 years of age compared to those aged 3 - < 8 years (10 - < 13 years HR: 2.12, 95% CI 1.42–3.18; > 13 years HR: 2.02, 95% CI 1.17–3.49), Cocker Spaniels (HR: 2.06, 95% CI 1.06–4.01, p = 0.034) compared to crossbreeds, a BG level at diagnosis > 40 mmol/L (HR: 2.75, 95% CI 1.35–5.57, p = 0.005) compared to < 20 mmol/L at diagnosis, or previous glucocorticoid treatment (HR: 1.83, 95% CI 1.20–2.80, p = 0.005). Factors associated with reduced hazard of death were neutered dogs (HR: 0.56, 95% CI 0.42–0.78, p < 0.001), Border Collies (HR: 0.39, 95% CI 0.17–0.87, p = 0.022) and dogs starting insulin treatment (HR: 0.08 95% CI 0.05–0.12, p < 0.001). Initiation of insulin treatment was associated with a variety of management methods in the first 3 months. To avoid collinearity, only insulin treatment was included in the final model. However the following management methods were all associated with increased survival when substituting them for insulin treatment and after adjusting for the other variables in the final model: BG curves at the practice (HR: 0.52, 95% CI 0.40–0.68, p < 0.001), recommended diet change (HR: 0.61, 95% CI 0.46–0.81, p = 0.001), fructosamine measurements (HR: 0.63, 95% CI 0.48–0.84, p = 0.002) and spot BG measurements (HR: 0.67, 95% CI 0.51–0.89, p = 0.004).
The clinic ID frailty term in the final multivariable model was not statistically significant (P = 0.497). Veterinary group confounded both neutering and breed associations with survival, and was therefore included. Inspection of the Nelson-Aalen cumulative hazard plots and Schoenfeld residuals (P = 0.113) suggested the proportional hazards assumption was not violated.
This is the largest study to date exploring risk factors for DM in dogs in primary-care practices. It is the first to look at data from across the whole of the UK, and to explore associations between initial management methods for DM and survival. Dogs > 8 years of age, female entire dogs, male neutered dogs, WHWT and Border Terrier breeds in particular, dogs documented as obese, or having a concurrent diagnosis of hyperadrenocorticism or pancreatitis were all associated with an increased odds of DM diagnosis. Variables associated with an increased hazard of death after diagnosis included dogs that were ≥ 10 years of age at diagnosis, entire, previously on glucocorticoids, having had a BG level > 40 mmol/L at diagnosis, or dogs that did not start insulin treatment.
The prevalence of DM in the current study (0.26%) was calculated for dogs aged 3 years or above, and therefore may not be directly comparable to the higher prevalence values of 0.32–0.36% reported by other UK and Australian studies assessing the overall population dogs within a primary-care setting [1,2,3]. However the current study may offer a more accurate representation of the wider UK dog population, as previous studies were limited to only insured dogs , or only data from England . Similarly, prevalence estimates of 0.64–1.33% reported by studies of hospital-based populations [11, 36] are likely to be biased due to the referred source population , and may not accurately reflect the wider dog population. In the current study, only 5.9% (24/409) of incident cases were referred for advanced management, highlighting the importance of studies from primary-care practice given that referral centres may be missing almost 95% of DM cases from the general dog population.
The annual incidence risk in dogs aged ≥3 years in the current study was estimated at 0.09% (95% CI: 0.08–0.09%). The study by Fall et al. (2007) on a Swedish insured dog population reported the cumulative proportion of dogs developing DM by 12 years of age as 1.2%, approximating to an annual incidence risk of 0.1% . It is very difficult to compare these two studies due to the different source populations and methodologies for calculating annual incidence risk. Human T1DM had a reported average annual increase of 2.8% worldwide between 1990 and 1999 , and previous studies have suggested that the incidence of canine DM may also be increasing [11, 12].
Diagnostic testing information was available for 95.8% (392/409) DM cases in the current study. Of these dogs 32.8% (134) were ketotic at diagnosis which, having been assessed via urinary dipsticks, is likely to be an under-estimate because this test will not detect all types of ketone bodies . This relatively high prevalence of ketosis at the time of diagnosis in primary care practice has not previously been reported. The same percentage of dogs (32.8%, 134) either presented with or developed cataracts within 3 months of DM diagnosis. The current study did not discriminate between diabetic and non-diabetic cataracts. However, some cases that developed cataracts may not have been documented in the clinical notes, suggesting that this figure could be an underestimate. Previous studies have reported 50% of diabetic dogs developing cataracts within 6 months [40, 41]. Although diabetic cataracts can be managed surgically, this is not always affordable for owners and ocular health was cited as a contributory reason for euthanasia in 14.2% (33/233) of all euthanasia decisions.
Age was strongly associated with the odds of diagnosis of DM. Consistent with other studies [2, 11], dogs over 8 years were at increased risk, with those aged 10 to < 13 years having over 7 times the odds of DM diagnosis compared to dogs aged 3 - < 8 years. No association was detected with sex, which is consistent with other studies [2, 14]. However, there was a strong association with the combined sex-neuter variable. Similar to previous findings, neutered males had almost twice the odds [2, 3, 11], and entire females had three times the odds of developing DM compared to entire males. Where there is a large entire female population, such as in Sweden, the increase in female cases of DM is thought to be a reflection of dioestrus diabetes . However, despite the evidence between hormonal changes in dioestrus and the development of diabetes [20, 26, 42], overall the current study found no significant difference between entire and neutered females in developing DM. Instead, it suggests that entire males may be “protected”. Cross-sectional studies in humans have reported that men with lower testosterone levels have an increased T2DM risk . In spontaneous mouse models of T1DM, such as the non-obese diabetic mouse, females are predisposed to diabetes, an effect thought to be mediated through testosterone-driven effects on the microbiome . Although the pathogenesis of DM in dogs is heterogeneous, one mechanism by which male entire dogs may be relatively protected is via increased testosterone. However, this hypothesis may only be relevant to a proportion of diabetes cases, and was not investigated directly in the present study.
Breed associations were consistent with previous findings [3, 13, 15, 16], and add weight to the evidence that DM has a genetic component [7, 13]. To identify new genes and potential treatment targets in canine diabetes, understanding which breeds are genetically protected from DM is just as important as identifying those with a predisposition. In an aim to explore the effect of breed on both predisposition and protection in the current study, breeds with ≥10 dogs within cases and controls combined, and/or breeds with ≥5 DM cases were included as individual breeds within the ‘breed’ variable. Other breeds falling outside this definition were combined as ‘purebred other’. This enabled these individual breeds to be evaluated within the multivariable logistic analysis, and after adjustment for other variables and confounders on breed, aiming to provide a more accurate understanding of associations compared to most previous studies that use univariable analysis only. However, despite 1205 dogs being taken forward to multivariable analysis, this categorisation was still under-powered to evaluate breeds adequately where there were very few or no cases, despite the breed itself being relatively common. In this respect, this study was unable to identify all breeds at high risk of developing DM, and the findings focus on the breeds that were commonly represented in the UK during 2016.
The current study identified that WHWTs and Border Terriers were “at risk”, having approximately 3 times the odds of DM compared to crossbreds. Samoyeds are frequently over-represented in DM cases in other studies and although there was only one Samoyed present in this case control study, it was a DM case. Breeds with reduced odds of DM compared to crossbreds included GSD and Shih-Tzu, as well as SBT, a breed consistent with suggestive findings in other studies , but not previously significantly associated with lower DM risk. Interestingly the current study contained 10 English Springer Spaniels and 10 Pugs, but there were no cases documented for either of these breeds. Pugs have not previously been associated with a decreased odds of DM, whereas English Springer Spaniels have been associated with both a reduced odds of DM in the UK , and an increased odds of DM in Australia . This suggests that different genetic subpopulations of English Springer Spaniels with different susceptibilities to DM may exist across these two geographical regions. This may be a useful area for further research into the genetics of DM in dogs.
Dogs documented as obese were associated with 2.7 times the odds of DM diagnosis (95% CI 1.63–4.52, p < 0.001). Despite no clear biological reason for obese dogs to be prone to DM due to insulin deficiency , this finding adds to evidence from other studies that obesity may be a risk factor for the disorder [2, 26], potentially by causing insulin resistance. The present study relied on subjective, unprompted recording of obesity by the veterinary professional, therefore under-reporting was likely, particularly with regards to controls, because cases had more detailed histories/examinations. Diet has also been associated with DM in dogs , and because obesity is often associated with poor dietary control and limited exercise , another explanation is that “obesity” may be acting as a proxy for other associated risk factors. It is clear that more research is required to establish the exact link between obesity in dogs and DM. Interestingly obesity was not associated with, nor confounded by, prior glucocorticoid treatment. The latter was associated with roughly double the odds of DM, which is likely to reflect insulin resistance caused by these drugs .
Concurrent hyperadrenocorticism and pancreatitis were both strongly associated with DM diagnosis, consistent with several other studies [2, 3, 17, 27]. The results should be interpreted with some caution because the numbers of controls with these conditions in this study were low, albeit consistent with the prevalence of these diseases (approx. 0.02–0.04%) in the wider UK dog population . The temporality, and causation, between pancreatitis and DM is also difficult to determine , and interestingly only 13% (6/46) of the pancreatitis diagnoses in the current study clearly preceded DM. In total pancreatitis was documented in an unprompted way in 11.3% of cases, similar to the 11.5% reported in a previous UK primary-care study , but less than the 17.7% reported in DM cases in primary-care practice in Australia , and the 19% reported by an Italian referral study . It is likely that pancreatitis is under-reported in the current study for both cases and controls due to non-specific clinical signs, and lack of definitive diagnostics being performed. Further research is required to fully understand the interplay between these two diseases.
Where recorded, the most common management methods for DM in the first 3 months were home or practice BG curves (70.6%, 255/361), followed by spot BG measurements (68.4%, 247), even though the latter is considered unreliable for monitoring . Only 4.2%  of dogs were managed by spot BG alone, suggesting this method is primarily used as an augmentation to other management techniques.. Identification of management techniques and diagnostics currently employed by primary-care clinicians by this study provides a benchmark against which individuals and clinics can compare their own processes and practices.
Median survival time for all dogs with DM was 15.6 months (95% CI: 10.4–20.0 months). This estimate is likely to be negatively skewed by inclusion of dogs where DM management was not realistically attempted. To account for this, an MST was calculated for all dogs surviving at least 7 days post diagnosis, estimated at 20.2 months (95% CI: 16.6–24.7 months). The all dogs MST estimated in this study is consistent with the 17.3 months reported by an earlier VetCompass study , but differs substantially from the reported MST of 2 months from a population of insured Swedish dogs , and of 32 months for dogs presenting to a referral hospital in Italy . This may reflect differences between countries, or that dogs presenting to a referral hospital are more likely to have motivated owners and access to gold standard level of care. Successful treatment of DM requires substantial owner commitment, and given that 92.5% of the dogs in the current study died due to an owner’s decision to euthanise, it is clear that MST is strongly influenced by a variety of owner-related factors such as their finances, lifestyle or perception of the condition.
Age at diagnosis, neuter status and breed have all previously been associated with DM survival [2, 16], and were also associated in the current study. Dogs aged ≥10 years and Cocker Spaniels had twice the hazard of death compared to dogs 3 to < 8 years and crossbreds respectively. Conversely, Border Collies and neutered animals had a lower hazard compared to crossbreds and entire animals. The differences in survival between breeds may reflect genetic differences involved in the pathogenesis of the disease. Interestingly previously studies have found a female predisposition to DM in Border Collies [13, 16], suggesting dioestrus diabetes may be more prevalent in this breed. In the current study 92.3% (12/13) of the Border Collie cases were females, with 6 of these were entire and 6 were neutered at the time of diagnosis. The increased survival found in this breed could therefore be partially related to survival associated with dioestrus diabetes cases, where remission may be possible following ovariohysterectomy. Whilst the clinical signs associated with canine DM, such as polyuria and polydipsia are relatively consistent, the underlying pathogenesis is relatively heterogeneous. More detailed and consistent clinical phenotyping at the time of diagnosis e.g. measurement of pancreatic inflammatory markers, would enable improved disease classification, allowing further insights to be gained into the relationship between underlying pathogenesis and survival.
Overall, neutered animals had a lower hazard of death once diagnosed (hazard ratio (HR): 0.56, 95% CI 0.42–0.78, p < 0.001) which is consistent with the findings of a previous UK primary-care study . There is no clear reason whether this is biological or due to neutering acting as a proxy for some other measure such as the owner’s ability and willingness to treat DM.
Insurance status and concurrent pancreatitis have previously been associated with survival in primary-care practice . Pancreatitis was cited as a cause of death in 7.3% (17/233) of euthanised cases, but in the current study did not identify an association between survival with insurance status, or the diagnosis of concurrent pancreatitis or hyperadrenocorticism at the time of DM diagnosis. A recent referral study similarly did not identify association with pancreatitis and survival , suggesting that pancreatitis, where recognised in the 3 months before or after diagnosis, may not significantly affect survival.
Other variables associated with survival in the current study included BG level at diagnosis, insulin treatment, and glucocorticoid treatment. Dogs with a BG reading > 40 mmol/L at diagnosis had a hazard ratio of 2.75 (95% CI: 1.35–5.57, p = 0.004) compared to dogs with a BG reading < 20 mmol/L. Higher BG levels at diagnosis may reflect “sicker” dogs or those in diabetic ketoacidosis, yet neither hospitalisation, or being ketotic at diagnosis, (a proxy measure for diabetic ketoacidosis) were associated with BG levels or survival. A referral study of incident cases reported that BG levels in untreated dogs were not associated with survival in multivariable analysis . Although this was a smaller study and limited to a referral caseload, these differing findings to the current study may reflect intrinsic differences between typical treatment options and survival in a referral versus primary-care setting. In primary-care practice, early identification of DM, before BG levels rise > 40 mmol/L, may be important for this population of dogs to have a better chance of stabilisation and survival. Dogs starting insulin had a significantly reduced hazard of death (HR: 0.08, 95% CI 0.05–0.12, p < 0.001), consistent with the fact that virtually all dogs are insulin dependent by the time of diagnosis . There was evidence from the current study that previous glucocorticoid treatment increased the hazard of death (HR: 1.83, 95% CI 1.20–2.80, p = 0.005). This may result from increased difficulties in managing DM concurrently with other disorders that require glucocorticoid treatment.
The presence of ketotis at diagnosis was not adversely associated with survival, and diabetic ketoacidosis was mentioned as a reason for euthanasia in only 3.4% of cases. Despite diabetic ketoacidosis potentially being a life-threatening condition, it appears not to be a driving factor for survival. This may reflect the confidence of primary practitioners in attempting treatment of the condition, rather than opting for euthanasia, or an under-reporting of the condition. The latter is likely to be true in this study where urine strips to identify ketones were used as a proxy for diabetic ketoacidosis at diagnosis, and where further investigations to diagnose diabetic ketoacidosis at the point of euthanasia was often not undertaken or reported in the clinical notes.
The study included information on a variety of management methods that were used to manage/monitor DM during the first 3 months following diagnosis, including BG curves at the practice, recommended diet change, spot BG and fructosamine measurements. At a univariable level, several of these methods were associated with increased survival. However, because these management methods were highly correlated with each other, and with insulin treatment, it was inappropriate to retain them all in the final model. Insulin treatment was retained as this had the greatest impact on the HR. Because dogs that survived longer had a longer duration of exposure to the chance of receiving management methods, it was aimed to minimise this survival-bias effect by restricting observations on management to the first 3 months post diagnosis. As many of the management methods were associated with increased survival, it can be argued that contact with the practice within these first few months is more important for survival than the type of management technique per se. This contact is likely to be a proxy for owner commitment and compliance, as well as the availability of support from the practice, and it has been argued that assessment of these on long term survival is more important than considering specific patient characteristics . Further studies into survival of DM cases should consider ways to capture this element of owner compliance.
There were a number of limitations to this study. As it relied on reviewing of retrospective Electronic Patient Records (EPRs), inconsistencies and inaccuracies within these may have led to either missing data, or misclassification for variables such as obesity/medications/concurrent conditions. Errors relating to these inconsistencies were more likely to occur with controls than cases because the latter group were more likely to have higher counts of veterinary visits and investigations for concurrent conditions. The number of dogs within each breed category was dependant on the popularity of that breed within the UK within 2016. This meant there was insufficient power to detect potentially significant differences within breeds where there were low numbers, for example the inability of this study to detect Samoyeds as high risk for developing DM. Additionally, although misclassification of DM was thought unlikely because this is a routine primary-care veterinary diagnosis, a veterinary diagnosis of pancreatitis or hyperadrenocorticism in DM cases may have been misclassified due to similarities in clinical signs or difficulties in interpreting diagnostic tests.
Middle-aged dogs, neutered males, specific breeds, glucocorticoid treatment and concurrent hyperadrenocorticism or pancreatitis were all associated with DM diagnosis in dogs. Additionally, there is an indication for further exploration of the associations between DM and obesity. Survival with DM is associated with age, breed and neutering. Survival was also associated with insulin treatment and BG level at diagnosis, suggesting early identification and treatment of DM patients in primary-care practice can help increase survival times. Awareness of these factors can aid veterinary professionals in the management and advice on prognosis after diagnosis of DM in dogs.
Study design and period
This study aimed to estimate prevalence and incidence, and investigate risk factors for DM and the survival of DM cases in dogs. This study used data from Electronic Patient Records (EPRs) of dogs attending UK primary-care veterinary practices collaborating within the VetCompass Programme. The study population consisted of the cohort of all dogs ≥3 years on the 1st January 2016 that were under the care of a VetCompass practice as evidenced by having an EPR during 2016, or in both 2015 and 2017. This study population was restricted to dogs ≥3 years for both cases and controls in order to exclude the less typical juvenile-onset DM cases which are likely to differ in their DM aetiology.
A nested case-control study was used to investigate risk factors for the diagnosis of DM, and the underlying study cohort was used to estimate prevalence, incidence and to examine survival post diagnosis. Sample size calculations estimated an unmatched case-control study would require approximately 350 cases and 700 controls to detect an odds ratio (OR) of at least 2.0 where at least 5% of the controls were exposed to the risk factor of interest (95% confidence level, 80% power, 1:2 case:control ratio) (OpenEpi v.3.012013). Ethical approval was granted by Royal Veterinary College Clinical Research Ethical Review Board (reference: SR2018–1652).
Data collection and management
Potential DM cases were identified by searching the EPRs for terms related to diabetes diagnosis/management within the free text clinical records (diab, insul, hyperg, mell, glucose, DM, ketoa, ketou, IDDM, fruct, curve, insuv, prozi, canins, vetp, vet pen), treatment records (canins, insul, prozi, neutral, lent, vetp, vet pen, insuv), and recorded VeNom diagnosis fields (Diabetes mellitus, Diabetes mellitus – unstable, Diabetes mellitus – stable, Diabetic ketoacidosis). The EPRs were examined manually to identify cases, and their date of diagnosis. A DM case was defined as a final veterinary diagnosis of DM, treatment with insulin, or strong evidence of a veterinary diagnosis based on evidence of hyperglycaemia, glucosuria and appropriate clinical signs in the EPR. The date of diagnosis was the earliest date of either veterinary confirmation of diagnosis, receipt of confirmatory test results, or initiation of insulin treatment. Dogs treated with insulin for hyperkalaemia without hyperglycaemia were excluded. Cases that were pre-existing or newly diagnosed during 2016 were used to estimate a one-year period prevalence. Only cases newly diagnosed during 2016 were retained for estimation of incidence and for the risk factor and survival analysis.
For each case, there were two control dogs randomly selected from the study population aged ≥3 years on 01/01/2016. Controls were excluded if the dog had pre-existing DM, developed DM prior to July 2019, or if the VetCompass record did not include evidence of direct owner/patient contact with the practice. To establish an equivalent to “date of diagnosis” for the controls, a random date in 2016 was generated for each dog and the nearest VetCompass record to this date was used to determine time-bound exposure variables.
Case and control demographic data extracted from VetCompass included: breed, date of birth, sex, neutering status, bodyweight, insurance status and veterinary group. Sex and neuter status were examined individually and also combined as a sex-neuter variable. Breeds were categorised as purebred or crossbred. Purebreds were further classified using the VeNom breed terms and analysed individually if they included ≥10 dogs and/or ≥ 5 DM cases in the overall case-control study. All purebred breeds containing < 10 dogs and/or < 5 DM cases were classified as purebred (other). Age was determined at the “date of diagnosis” and categorised into quartiles that grossly corresponded to 3 to < 8, 8 to < 10, 10 to < 13, and > 13 years. Adult mean bodyweight was calculated from all bodyweight data recorded from 18 months of age for each dog and used to classify dogs as at/above or below their breed/sex mean value. Veterinary group was categorised A – E; each group consisted of clinics that were part of the same parent company. The clinical records were examined manually to extract data on obesity, systemic glucocorticoid treatment within 6 weeks prior to diagnosis, or concurrent (+/− 3 months of diagnosis) diagnosis of pancreatitis or hyperadrenocorticism. Presence of obesity was recorded when there was evidence of a veterinary surgeon/nurse classifying the dog as very overweight, obese, or BCS ≥ 4/5 or ≥ 8/10, either at diagnosis or within the preceding 12 months. Evidence of pancreatitis was determined by a final veterinary diagnosis of pancreatitis, or a canine pancreatic lipase immunoreactivity of ≥400 μg/l. A diagnosis of hyperadrenocorticism included any dog initiated on trilostane treatment. Evidence for these latter two conditions was extended to +/− 3 months of diagnosis to account for similarities to DM in presenting signs, and unreliability of some hyperadrenocorticism tests in unstable diabetic dogs .
Survival analysis additionally included variables describing which diagnostic tests were used (urinalysis, BG, fructosamine, unspecified blood tests), BG level at diagnosis (as determined by a handheld glucometer, inhouse blood analyser, or via an external laboratory), evidence of ketosis at diagnosis (defined as a ketone recording of ≥1 on a urinalysis strip at or within 3 days of presentation, and prior to initiating insulin treatment), presence of cataracts within 3 months of diagnosis, referral for advanced clinical management, hospitalisation, initial insulin treatment regime, and management methods for the first 3 months (home BG measurements, BG curve, fructosamine, spot BG – defined as no more than one reading taken in 24 h, unspecified blood tests, urinalysis, recommended diet change). BG level at diagnosis was split primarily around the median and then 4 categories were created to reflect divisions of BG from above the renal threshold value (approx. 11.1 mmol/L) to the upper limit detected by handheld blood glucometers (approx. 40 mmol/L). These categories correspond to < 20 mmol/L, 20–30 mmol/L, 30–40 mmol/L, and > 40 mmol/L. Information on the date and cause of all deaths prior to February 2020 was extracted from the EPR. Records not explicitly recording death were censored at the date of the last practice-patient interaction prior to February 2020. Diabetes mellitus was recorded as the cause of death for deaths that occurred subsequent to the worsening of clinical signs. Euthanised cases were further classified as condition worsening, inability to cope with condition (owner), financial considerations, concurrent conditions or other. Data entry errors were minimised by a secondary coder checking every case and 15% of controls.
Data were checked and cleaned in Microsoft Excel before exporting to Stata for analysis. One-year period prevalence was calculated as the number of newly diagnosed and pre-existing DM cases present in 2016 within the study population. Annual incidence risk with 95% confidence interval (CI) was calculated as the proportion of newly diagnosed DM cases in 2016 within the study population of dogs ≥3 years old on 01/01/2016.
The case-control study used univariable binary logistic regression modelling to explore associations between potential risk factors and the development of DM. Variables with a likelihood ratio test (LRT) of p < 0.2 were taken forward to multivariable analysis. Where checks for multicollinearity identifies an association, the variable with the lowest p-value within the multivariable model was retained. A manual forward selection method was used to build the final multivariable logistic regression model, retaining variables with a likelihood ratio test of P < 0.05. Final model variables were assessed for pairwise interaction effects using the LRT, confounding was assessed by evaluating for a > 10% change in parameter estimates, and all confounders were included in the final model. Clustering at the veterinary practice level was evaluated by including clinic ID as a random effect. Model fit was assessed using the Hosmer-Lemeshow test statistic , and statistical significance was set at 5%.
Median survival time was calculated for all-cause mortality, defined as the time from DM diagnosis until the cumulative survival proportion reached 50% . Median survival time was calculated for all dogs, and also for a subset of dogs that survived at least day 7 following diagnosis. Cox regression modelling was used to assess associations with survival for all dogs. Variables associated with survival (P < 0.2) in the univariable analysis were taken forward to the multivariable analysis. Multivariable modelling used the same criteria as the logistic regression. Clinic ID was included as a frailty term to evaluate clustering at the practice level. The proportional hazards assumption was evaluated with Schoenfeld residuals and visual inspection of the Nelson-Aalen cumulative hazard plot. Statistical significance was set at 5%.
Availability of data and materials
The VetCompass™ dataset used for this study are available open access on the RVC data repository, http://researchonline.rvc.ac.uk/id/eprint/12622/
West Highland White Terrier
Staffordshire Bull Terrier
German Shepherd Dog
Human Type 1 diabetes mellitus
Human Type 2 diabetes mellitus
Median survival time
Likelihood ratio test
Catchpole B, Ristic JM, Fleeman LM, Davison LJ. Canine diabetes mellitus: can old dogs teach us new tricks? Diabetologia. 2005 Oct 1;48(10):1948–56.
Mattin MJ, O’Neill DG, Church DB, McGreevy PD, Thomson PC, Brodbelt DC. An epidemiological study of diabetes mellitus in dogs attending first opinion practice in the UK. Vet Microbiol. 2014;174(14):349.
Yoon S, Fleeman LM, Wilson BJ, Mansfield CS, McGreevy P. Epidemiological study of dogs with diabetes mellitus attending primary care veterinary clinics in Australia. Vet Rec [Internet]. 2020 Feb 12 [cited 2020 Feb 19]; Available from: https://veterinaryrecord.bmj.com/content/early/2020/02/12/vr.105467.
Nelson RW. Canine Diabetes Mellitus. In: Canine and Feline Endocrinology. Fourth Edition; 2015. p. 213–57.
ESVE. ESVE Project Alive [Internet]. 2015 [cited 2020 Mar 18]. Available from: https://www.esve.org/alive/search.aspx.
Gilor C, Niessen SJM, Furrow E, DiBartola SP. What’s in a name? Classification of diabetes mellitus in veterinary medicine and why it matters. J Vet Intern Med. 2016;30(4):927–40.
Catchpole B, Kennedy LJ, Davison LJ, Ollier WER. Canine diabetes mellitus: from phenotype to genotype. J Small Anim Pract. 2019:4–10.
Davison LJ, Ristic JME, Herrtage ME, Ramsey IK, Catchpole B. Anti-insulin antibodies in dogs with naturally occurring diabetes mellitus. Vet Immunol Immunopathol. 2003 Jan 10;91(1):53–60.
Nelson RW, Reusch CE. Animal models of disease: classification and etiology of diabetes in dogs and cats. J Endocrinol. 2014 Sep;222(3):T1–9.
DIAMOND Project Group. Incidence and trends of childhood type 1 diabetes worldwide 1990-1999. Diabet Med J Br Diabet Assoc. 2006 Aug;23(8):857–66.
Guptill L, Glickman L, Glickman N. Time trends and risk factors for diabetes mellitus in dogs: analysis of veterinary medical Data Base records (1970–1999). Vet J. 2003 May 1;165(3):240–7.
Aja D. Banfield state of pet health report 2016. Vancover: Banfield Pet Hospital; 2016.
Catchpole B, Adams JP, Holder AL, Short AD, Ollier WER, Kennedy LJ. Genetics of canine diabetes mellitus: are the diabetes susceptibility genes identified in humans involved in breed susceptibility to diabetes mellitus in dogs? Vet J Lond Engl 1997. 2013;195(2):139–47.
Davison LJ, Herrtage ME, Catchpole B. Study of 253 dogs in the United Kingdom with diabetes mellitus. Vet Rec. 2005 Apr 9;156(15):467–71.
Marmor M, Willeberg P, Glickman LT, Priester WA, Vm D, Cypess RH, et al. Epizootiologic patterns of diabetes mellitus in dogs. Am J Vet Res. 1982;43(3):465–70.
Fall T, Hamlin HH, Hedhammar Å, Kämpe O, Egenvall A. Diabetes mellitus in a population of 180,000 insured dogs: incidence, survival, and breed distribution. J Vet Intern Med. 2007;21(6):1209–16.
Hess RS, Kass PH, Ward CR. Breed distribution of dogs with diabetes mellitus admitted to a tertiary care facility. J Am Vet Med Assoc. 2000 May 1;216(9):1414–7.
Bellumori TP, Famula TR, Bannasch DL, Belanger JM, Oberbauer AM. Prevalence of inherited disorders among mixed-breed and purebred dogs: 27,254 cases (1995-2010). J Am Vet Med Assoc. 2013 Jun 1;242(11):1549–55.
Usui S, Yasuda H, Koketsu Y. Characteristics of dogs having diabetes mellitus; analysis of data from private Japanese veterinary clinics. Vet Med Anim Sci. 2015;3(1):5.
Eigenmann JE, Eigenmann RY, Rijnberk A, van der Gaag I, Zapf J, Froesch ER. Progesterone-controlled growth hormone overproduction and naturally occurring canine diabetes and acromegaly. Acta Endocrinol. 1983 Oct;104(2):167–76.
Doxey DL, Milne EM, Mackenzie CP. Canine diabetes mellitus: a retrospective survey. J Small Anim Pract. 1985;26(9):555–61.
Ihedioha JI, Enahoro G. Prevalence of diabetes mellitus and reference values for the fasting blood glucose levels of locally available breeds of dogs in Warri, Nigeria. Comp Clin Pathol [Internet]. 2019 Mar 29 [cited 2019 Jun 17]; Available from: https://doi.org/10.1007/s00580-019-02938-7.
Hoenig M. Comparative aspects of human, canine, and feline obesity and factors predicting progression to diabetes. Vet Sci. 2014 Sep;1(2):121–35.
Verkest KR, Rand JS, Fleeman LM, Morton JM, Richards AA, Rose FJ, et al. Distinct adiponectin profiles might contribute to differences in susceptibility to type 2 diabetes in dogs and humans. Domest Anim Endocrinol. 2011 Aug 1;41(2):67–73.
Klinkenberg H, Sallander MH, Hedhammar A. Feeding, exercise, and weight identified as risk factors in canine diabetes mellitus. J Nutr. 2006 Jul;136(7 Suppl):1985S–7S.
Pöppl AG, de Carvalho GLC, Vivian IF, Corbellini LG, González FHD. Canine diabetes mellitus risk factors: a matched case-control study. Res Vet Sci. 2017 Oct 1;114:469–73.
Hume DZ, Drobatz KJ, Hess RS. Outcome of dogs with diabetic ketoacidosis: 127 dogs (1993-2003). J Vet Intern Med. 2006 Jun;20(3):547–55.
Blois SL, Dickie E, Kruth SA, Allen DG. Multiple endocrine diseases in dogs: 35 cases (1996-2009). J Am Vet Med Assoc. 2011 Jun 15;238(12):1616–21.
Miceli DD, Pignataro OP, Castillo VA. Concurrent hyperadrenocorticism and diabetes mellitus in dogs. Res Vet Sci. 2017 Dec;115:425–31.
Bostrom BM, Xenoulis PG, Newman SJ, Pool RR, Fosgate GT, Steiner JM. Chronic pancreatitis in dogs: a retrospective study of clinical, clinicopathological, and histopathological findings in 61 cases. Vet J Lond Engl 1997. 2013;195(1):73–9.
Watson PJ, Archer J, Roulois AJ, Scase TJ, Herrtage ME. Observational study of 14 cases of chronic pancreatitis in dogs. Vet Rec. 2010 Dec 18;167(25):968–76.
Davison LJ. Diabetes mellitus and pancreatitis - cause or effect? J Small Anim Pract. 2015 Jan;56(1):50–9.
Pápa K, Máthé A, Abonyi-Tóth Z, Sterczer A, Psáder R, Hetyey C, et al. Occurrence, clinical features and outcome of canine pancreatitis (80 cases). Acta Vet Hung. 2011 Mar;59(1):37–52.
Tardo AM, Baldo FD, Dondi F, Pietra M, Chiocchetti R, Fracassi F. Survival estimates and outcome predictors in dogs with newly diagnosed diabetes mellitus treated in a veterinary teaching hospital. Vet Rec. 2019 Dec 7;185(22):692.
Niessen SJM, Hazuchova K, Powney SL, Guitian J, Niessen APM, Pion PD, et al. The Big Pet Diabetes Survey: Perceived Frequency and Triggers for Euthanasia. Vet Sci. 2017;4(2) Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5606606/ [cited 2019 Jul 24].
Fracassi F, Pietra M, Boari A, et al. Breed distribution of canine diabetes mellitus in Italy. Vet Res Commun. 2004;28(Suppl):339–42.
Bartlett PC, Van Buren JW, Neterer M, Zhou C. Disease surveillance and referral bias in the veterinary medical database. Prev Vet Med. 2010 May 1;94(3–4):264–71.
Dohoo I, Martin W, Stryhn H. Measures of disease frequency. In: Veterinary epidemiologic research. 2nd ed. Charlottetown: VER Inc; 2009. p. 75–9.
Laffel L. Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes. Diabetes Metab Res Rev. 1999;15(6):412–26.
Beam C. Davidson. A retrospective-cohort study on the development of cataracts in dogs with diabetes mellitus: 200 cases. Vet Ophthalmol. 1999;2(3):169–72.
Miller EJ, Brines CM. Canine diabetes mellitus associated ocular disease. Top Companion Anim Med. 2018 Mar 1;33(1):29–34.
Fall T, Hedhammar A, Wallberg A, Fall N, Ahlgren KM, Hamlin HH, et al. Diabetes mellitus in elkhounds is associated with diestrus and pregnancy. J Vet Intern Med. 2010 Dec;24(6):1322–8.
Haffner SM, Karhapää P, Mykkänen L, Laakso M. Insulin resistance, body fat distribution, and sex hormones in men. Diabetes. 1994 Feb;43(2):212–9.
Markle JGM, Frank DN, Mortin-Toth S, Robertson CE, Feazel LM, Rolle-Kampczyk U, et al. Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity. Science. 2013 Mar 1;339(6123):1084–8.
Volaco A, Cavalcanti AM, Filho RP, Précoma DB. Socioeconomic status: the missing link between obesity and diabetes mellitus? Curr Diabetes Rev. 2018;14(4):321–6.
Campbell KL, Latimer KS. Transient diabetes mellitus associated with prednisone therapy in a dog. J Am Vet Med Assoc. 1984 Aug 1;185(3):299–301.
VetCompass. VetCompass Infographics. Disease prevalence data for UK pet dogs. [Internet]. Royal Veterinary College; 2019 [cited 2019 Aug 19]. Available from: https://www.rvc.ac.uk/vetcompass/learn-zone/infographics/canine/.
Behrend E, Holford A, Lathan P, Rucinsky R, Schulman R. 2018 AAHA diabetes management guidelines for dogs and cats. J Am Anim Hosp Assoc. 2018 Jan 1;54(1):1–21.
Gilor C. Discussing prognosis for canine diabetes mellitus: do we have relevant data? Vet Rec. 2019 Dec 7;185(22):689–91.
Kaplan AJ, Peterson ME, Kemppainen RJ. Effects of disease on the results of diagnostic tests for use in detecting hyperadrenocorticism in dogs. J Am Vet Med Assoc. 1995;207(4):445–51.
Hosmer DW, Lemeshow S. Assessing the Fit of the Model. In: Applied Logistic Regression: Wiley; 2005. p. 143–202. [cited 2019 Aug 19] Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/0471722146.ch5.
Jager KJ, van Dijk PC, Zoccali C, Dekker FW. The analysis of survival data: the Kaplan–Meier method. Kidney Int. 2008 Sep 1;74(5):560–5.
Thanks to Noel Kennedy (RVC) for VetCompass™ software and programming development. We acknowledge the Medivet Veterinary Partnership, Vets4Pets/Companion Care, Goddard Veterinary Group, Independent Vet Care, Linnaeus Group, CVS Group, Beaumont Sainsbury Animal Hospital, Vets Now and the other UK practices who collaborate in VetCompass™. We are grateful to The Kennel Club and The Kennel Club Charitable Trust for supporting VetCompass™.
LJD receives funding from the Medical Research Council as an MRC Clinician Scientist Fellow (MR/R007977/1).
Ethics approval and consent to participate
Ethical approval was granted by the RVC Ethics and Welfare Committee (reference number 2015/1369).
Consent for publication
The authors have no conflicts of interest to declare.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Heeley, A.M., O’Neill, D.G., Davison, L.J. et al. Diabetes mellitus in dogs attending UK primary-care practices: frequency, risk factors and survival. Canine Genet Epidemiol 7, 6 (2020). https://doi.org/10.1186/s40575-020-00087-7
- Diabetes mellitus
- Risk factors
- Case-control study